REGENXBIO Inc.
RGNX$536M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaROCKVILLE
Clinical-stage biotechnology company developing AAV gene therapies
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 12, 2026
11wMarket Overview
Stock performance and key metrics
RGNX News
Catalyst Timeline
1 upcoming, 2 past
Drug Pipeline
No drugs found in this phase.
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply